969
Views
28
CrossRef citations to date
0
Altmetric
Review

Strategies to induce broadly protective antibody responses to viral glycoproteins

Pages 503-513 | Received 02 Jan 2017, Accepted 22 Feb 2017, Published online: 17 Mar 2017
 

ABSTRACT

Introduction: Currently, several universal/broadly protective influenza virus vaccine candidates are under development. Many of these vaccines are based on strategies to induce protective antibody responses against the surface glycoproteins of antigenically and genetically diverse influenza viruses. These strategies might also be applicable to surface glycoproteins of a broad range of other important viral pathogens.

Areas covered: Common strategies include sequential vaccination with divergent antigens, multivalent approaches, vaccination with glycan-modified antigens, vaccination with minimal antigens and vaccination with antigens that have centralized/optimized sequences. Here we review these strategies and the underlying concepts. Furthermore, challenges, feasibility and applicability to other viral pathogens are discussed.

Expert commentary: Several broadly protective/universal influenza virus vaccine strategies will be tested in humans in the coming years. If successful in terms of safety and immunological readouts, they will move forward into efficacy trials. In the meantime, successful vaccine strategies might also be applied to other antigenically diverse viruses of concern.

Declaration of interest

The Icahn School of Medicine at Mount Sinai has filed several patents related to influenza virus vaccines with Krammer F being named as a co-inventor. Furthermore, the Krammer laboratory at the Icahn School of Medicine receives research funding from GlaxoSmithKline. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

Work in the Krammer Laboratory is funded by NIAID grants and contracts (R01 AI117287, U19AI109946 and HHSN272201400008C), the Bill and Melinda Gates Foundation, PATH and GlaxoSmithKline.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.